EE133 COST-EFFECTIVENESS ANALYSIS OF PAZOPANIB VERSUS SUNITINIB FOR THE TREATMENT OF FIRST-LINE ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA IN CHINA: USING PARTITIONED SURVIVAL MODEL AND MARKOV MODEL
Abstract
Authors
H Jia P Miao